Andrew Strong

Jan 4, 2024 | jdsupra.com | Penny Powell |Jodi Scott |Andrew Strong

January 4, 2024 Penny Powell, Jodi Scott, Andrew Strong Hogan Lovells + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: Cell, tissue, and gene therapies (CTGT) have for years offered the potential for truly personalized medicine for many near-incurable disease indications.

Jan 4, 2024 | lexology.com | Penny Powell |Jodi Scott |Andrew Strong

The annual J.P. Morgan Healthcare Conference (JPM) provides a unique opportunity to make connections among life sciences and health care emerging companies, pharma/biotech companies, investors, and advisors. This is an article in our “Life Sciences Transactional Insights” series, which aims to provide key practical takeaways for our transactional colleagues by anticipating the needs of their regulatory, intellectual property, and business stakeholders.

Oct 12, 2023 | lexology.com | Robert Church |Mike Druckman |Heidi Forster Gertner |Andrew Strong |Blake Wilson

On September 29, 2023, the U.S. Food and Drug Administration (FDA or "agency") announced the opportunity for a limited number of sponsors to participate in a new pilot program called Support for clinical Trials Advancing Rare disease Therapeutics (START) that will offer additional meetings with the agency to sponsors of novel drugs that aim to treat rare diseases.